CA3231451A1 - Sstr4 agonist salts - Google Patents

Sstr4 agonist salts Download PDF

Info

Publication number
CA3231451A1
CA3231451A1 CA3231451A CA3231451A CA3231451A1 CA 3231451 A1 CA3231451 A1 CA 3231451A1 CA 3231451 A CA3231451 A CA 3231451A CA 3231451 A CA3231451 A CA 3231451A CA 3231451 A1 CA3231451 A1 CA 3231451A1
Authority
CA
Canada
Prior art keywords
formula
compound
compound according
pain
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231451A
Other languages
English (en)
French (fr)
Inventor
David Andrew Coates
David Michael Remick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3231451A1 publication Critical patent/CA3231451A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3231451A 2021-09-14 2022-09-14 Sstr4 agonist salts Pending CA3231451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243785P 2021-09-14 2021-09-14
US63/243,785 2021-09-14
PCT/US2022/076401 WO2023044326A1 (en) 2021-09-14 2022-09-14 Sstr4 agonist salts

Publications (1)

Publication Number Publication Date
CA3231451A1 true CA3231451A1 (en) 2023-03-23

Family

ID=83508479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231451A Pending CA3231451A1 (en) 2021-09-14 2022-09-14 Sstr4 agonist salts

Country Status (19)

Country Link
US (2) US11834435B2 (https=)
EP (1) EP4402136A1 (https=)
JP (2) JP2024533482A (https=)
KR (1) KR20240056751A (https=)
CN (1) CN117940413A (https=)
AR (1) AR127055A1 (https=)
AU (1) AU2022348561B2 (https=)
CA (1) CA3231451A1 (https=)
CL (2) CL2024000683A1 (https=)
CO (1) CO2024003038A2 (https=)
CR (1) CR20240118A (https=)
DO (1) DOP2024000050A (https=)
EC (1) ECSP24020256A (https=)
IL (1) IL311251A (https=)
JO (1) JOP20240053A1 (https=)
MX (1) MX2024003119A (https=)
PE (1) PE20240885A1 (https=)
TW (3) TWI860849B (https=)
WO (1) WO2023044326A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
AU2024236692A1 (en) * 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2025096300A1 (en) * 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
TW202600537A (zh) 2024-03-11 2026-01-01 美商美國禮來大藥廠 Ｓｓｔｒ４促效劑化合物及其組合物
GB202408483D0 (en) 2024-06-13 2024-07-31 Maxion Therapeutics Ltd Receptor agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159941A (en) 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
FI20031454A0 (fi) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
US20100004339A1 (en) 2003-10-06 2010-01-07 Oy Juvantia Pharma Ltd. Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists
RS20060190A (sr) 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
GB0616574D0 (en) 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2729767A1 (en) 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2010059922A1 (en) 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
CN102675290B (zh) 2011-03-18 2014-11-12 山东亨利医药科技有限责任公司 含有并环的二氢吡唑类化合物
KR101556318B1 (ko) 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
WO2016075239A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
JP7774312B2 (ja) 2020-05-21 2025-11-21 クワンチョウ フェルミオン テクノロジー カンパニー リミテッド 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用
WO2021233428A1 (zh) 2020-05-21 2021-11-25 广州费米子科技有限责任公司 含氮饱和杂环化合物及其制备方法、药物组合物和应用
WO2022012534A1 (zh) 2020-07-13 2022-01-20 广州费米子科技有限责任公司 含氮杂环化合物、药物组合物和应用
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽

Also Published As

Publication number Publication date
CN117940413A (zh) 2024-04-26
MX2024003119A (es) 2024-04-09
ECSP24020256A (es) 2024-04-30
TWI860849B (zh) 2024-11-01
TWI822326B (zh) 2023-11-11
TW202400577A (zh) 2024-01-01
JP2024533482A (ja) 2024-09-12
AU2022348561B2 (en) 2025-05-22
IL311251A (en) 2024-05-01
US12486249B2 (en) 2025-12-02
AR127055A1 (es) 2023-12-13
EP4402136A1 (en) 2024-07-24
JP2025111617A (ja) 2025-07-30
TW202444703A (zh) 2024-11-16
CR20240118A (es) 2024-04-25
CO2024003038A2 (es) 2024-04-18
TW202330492A (zh) 2023-08-01
CL2025002158A1 (es) 2025-11-07
WO2023044326A1 (en) 2023-03-23
PE20240885A1 (es) 2024-04-24
US11834435B2 (en) 2023-12-05
JOP20240053A1 (ar) 2024-03-12
CL2024000683A1 (es) 2024-08-23
KR20240056751A (ko) 2024-04-30
DOP2024000050A (es) 2024-04-30
AU2022348561A1 (en) 2024-03-14
US20230099116A1 (en) 2023-03-30
US20240067628A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
AU2022348561B2 (en) Sstr4 agonist salts
EP4025572B1 (en) Heterocyclic rip1 kinase inhibitors
CN111433196B (zh) 缓激肽b2受体拮抗剂及其用途
AU2021203351A1 (en) Salts of a pim kinase inhibitor
ES2775614T3 (es) Sales de derivado de quinazolina y método de preparación de las mismas
CN113906020B (zh) 环状缓激肽b2受体拮抗剂
CA2983611A1 (en) Treatment of chronic graft versus host disease with syk inhibitors
JP2008531677A (ja) ペプチド様化合物及び生物活性誘導体の製造
WO2023124824A1 (zh) 一种glp-1激动剂的盐及其晶型和在医药上的应用
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
BR112020021224A2 (pt) processo para preparar moduladores de p300 e/ou cbp
TW202421139A (zh) 一種含氮雜環類化合物的可藥用鹽、晶型及製備方法
CN118715224B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
WO2021100019A1 (en) Prodrugs of abiraterone
JP2024533674A (ja) イミダゾリノン誘導体の結晶形
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
EA050624B1 (ru) Соли агониста sstr4
CN120025283B (zh) 酰胺类化合物及其用途
CN113906018B (zh) 缓激肽b2受体拮抗剂
WO2026061491A1 (zh) 一种苯并吲哚衍生物的晶型、盐型及其制备方法
CN114945565A (zh) 一种吡咯烷基脲衍生物的晶型及其应用
HK40009770A (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
HK40009770B (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250312

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260421

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421